Loading
Led SELECT (lenvatinib) and the ESTIMABL trials that showed many thyroid cancer patients can have lower radioiodine doses or none at all.
Martin Schlumberger was principal investigator of SELECT, which established lenvatinib for radioiodine-refractory differentiated thyroid cancer, and led ESTIMABL1 and ESTIMABL2, the French trials showing that low-dose radioiodine, and for low-risk patients no radioiodine, are non-inferior to standard ablation, sharply de-escalating thyroid cancer treatment. He has chaired the European Thyroid Association and ATA guideline work.
Shares Gustave Roussy, Thyroid cancer and the tag thyroid.
Shares Thyroid cancer, Small-molecule kinase inhibitors and the tag thyroid.
Shares Thyroid cancer, Small-molecule kinase inhibitors and the tag thyroid.
Shares Thyroid cancer, Small-molecule kinase inhibitors and the tag thyroid.
Shares Thyroid cancer and the tag thyroid.
Shares Thyroid cancer and the tag thyroid.
Shares SELECT, Thyroid cancer.
Shares Thyroid cancer and the tag thyroid.